We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 20 for:    leptin and type 1 diabetes

Corneal Confocal Microscopy in Patients With Type 1 Diabetes (CCM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03045250
Recruitment Status : Not yet recruiting
First Posted : February 7, 2017
Last Update Posted : February 7, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Assessing the use of corneal confocal microscopy to evaluate for early neuropathy changes in subjects with Type 1 Diabetes.

Condition or disease Intervention/treatment
Diabetic Neuropathies Device: Corneal confocal microscopy Procedure: Skin biopsy Procedure: Nerve conduction study Other: Blood draw

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Corneal Confocal Microscopy in Patients With Type 1 Diabetes
Anticipated Study Start Date : May 1, 2017
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : February 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Subjects with known Type 1 Diabetes
Subjects with known Type 1 diabetes
Device: Corneal confocal microscopy
Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
Procedure: Skin biopsy
Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
Procedure: Nerve conduction study
Nerve conduction studies will be use to assess for neuropathy.
Other: Blood draw
Subjects will undergo a one time blood draw for biomarkers.
Placebo Comparator: Healthy Controls
Healthy controls
Device: Corneal confocal microscopy
Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
Procedure: Nerve conduction study
Nerve conduction studies will be use to assess for neuropathy.
Other: Blood draw
Subjects will undergo a one time blood draw for biomarkers.


Outcome Measures

Primary Outcome Measures :
  1. Estimate corneal small nerve fiber damage in young T1DM subjects (corneal fiber density, nerve branch density, and fiber length) and compare the results to healthy controls using corneal confocal microscopy (CCM). [ Time Frame: Assessed one time per subject, study to be completed over 3 years ]
    Estimate corneal small nerve fiber damage in young T1DM subjects (corneal fiber density, nerve branch density, and fiber length) and compare the results to healthy controls using corneal confocal microscopy (CCM). This will be done by examining the cornea via confocal microscopy and obtaining images. These images will be evaluated looking at how many nerves there are, how they branch, and how long they are).

  2. Estimate corneal nerve fiber damage in subjects with diabetes with peripheral neuropathy and subjects with diabetes without peripheral neuropathy, diagnosed by skin biopsy. [ Time Frame: Assessed one time per subject, study to be completed over 3 years ]
    Estimate corneal nerve fiber damage in subjects with diabetes with peripheral neuropathy and subjects with diabetes without peripheral neuropathy, diagnosed by skin biopsies (a small skin biopsy will be taken, and the number of nerve fibers in the outer layer will be counted) and nerve conduction studies which measure the time it takes for an impulse to move through a nerve. This is done by the use of small electrodes placed on the limb)

  3. Obtain much needed normative values for CCM in adolescents and intraepidermal nerve fiber density from skin biopsies in subjects with type 1 diabetes. [ Time Frame: Assessed one time per subject, study to be completed over 3 years ]
    Obtain much needed normative values for CCM in adolescents and intraepidermal nerve fiber density from skin biopsies in subjects with type 1 diabetes. This will be done by obtaining a small biopsy of skin and looking at the number of nerve fibers in the outer layer of the skin.


Secondary Outcome Measures :
  1. As a secondary outcome measure, to compare serum biomarkers (blood levels) including leptin, TNF alpha, and fibrinogen in patients with diabetes comparing the blood level measurements of those with neuropathy vs. those without neuropathy. [ Time Frame: Assessed one time per subject, study to be completed over 3 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion:

  • Subjects with diabetes:
  • 18-30 years (cohort 1), adolescents ages 13-17 years (cohort 2).
  • Type 1 Diabetes diagnosed via standard ADA criteria

Matched Controls:

  • Match for age and gender
  • Hemoglobin A1c <6.5%

Exclusion:

For all subjects:

  • Contact lens wearers
  • Diseases that could damage the cornea, other than diabetes.
  • Neurologic disease
  • Psychiatric disease
  • Amputation
  • Foot ulcers
  • Pain not of neuropathic origin.
  • Presence of Lupus, Sjogren's syndrome and Celiac disease
  • Hyperlipidemia requiring lipid-lowering medications
  • Peripheral vascular disease
  • Neuropathy due to anything besides diabetes
  • Presence of any medical condition that may affect nerve conduction (e.g., radiculopathy).

For healthy controls

  • Family history of Type 1 Diabetes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03045250


Contacts
Contact: Lisa J Underland, DO 718 920 4664 ext 4155 lunderla@montefiore.org
Contact: Ranjitha Katikaneni, MBBS 718 920 4664 rkatikan@montefiore.org

Sponsors and Collaborators
Albert Einstein College of Medicine, Inc.
More Information

Responsible Party: Rubina Heptulla, Physician, Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier: NCT03045250     History of Changes
Other Study ID Numbers: 2016-6962
First Posted: February 7, 2017    Key Record Dates
Last Update Posted: February 7, 2017
Last Verified: February 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Diabetes Complications
Diabetic Neuropathies
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases